^
    BIOMARKER:

    CD19 positive

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    Entrez ID:
    930
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    CD19 positive
    B Acute Lymphoblastic Leukemia
    T-lymphocyte cell therapy
    Sensitive: C3 – Early Trials
    EHA 2022 - 2 weeks - (New C3)
    CD19 positive
    NHL
    tisagenlecleucel-T
    Sensitive: C3 – Early Trials
    EHA 2022 - 2 weeks - (New C3)
    CD19 positive
    B Acute Lymphoblastic Leukemia
    blinatumomab
    Sensitive: A1 - Approval
    BeiGene Press Release - 3 weeks - (New A1)
    CD19 positive
    ALL
    blinatumomab
    Sensitive: A1 - Approval
    CD19 positive
    B Acute Lymphoblastic Leukemia
    CTX110
    Sensitive: B - Late Trials
    CD19 positive
    NHL
    CTX110
    Sensitive: B - Late Trials
    CD19 positive
    B Acute Lymphoblastic Leukemia
    CAR-T immunotherapy
    Sensitive: C3 – Early Trials
    CD19 positive
    B Acute Lymphoblastic Leukemia
    YT-19
    Sensitive: C3 – Early Trials
    CD19 positive
    B Acute Lymphoblastic Leukemia
    tisagenlecleucel-T
    Sensitive: C3 – Early Trials
    CD19 positive
    B Acute Lymphoblastic Leukemia
    PBCAR0191
    Sensitive: C3 – Early Trials
    CD19 positive
    Small Lymphocytic Lymphoma
    T-lymphocyte cell therapy
    Sensitive: C4 – Case Studies
    CD19 positive
    CLL
    T-lymphocyte cell therapy
    Sensitive: C4 – Case Studies
    CD19 positive
    ALL
    FT596
    Sensitive: D – Preclinical
    CD19 positive
    NHL
    ISIKOK-19
    Sensitive: D – Preclinical
    CD19 positive
    B Acute Lymphoblastic Leukemia
    ISIKOK-19
    Sensitive: D – Preclinical